tbuckley/cabot-search huggingface dataset:
Long-term Mortality After Primary Prevention for Cardiovascular Disease-Reply
Authors: Paul Oglesby
Journal: JAMA (1992)

<h3>In Reply.</h3> —Nobody would disagree with Newman and colleagues that there is an apparent excess of violent deaths in some cholesterol-lowering trials, as well as in a recently reported meta-analysis.<sup>1</sup>Whether the findings achieve statistical significance as well as the magnitude of the<i>P</i>values, however, is in dispute depending on the numbers cited from individual trials (R. Peto, personal communication). If attention is restricted to the complete scheduled treatment period in all the primary prevention trials of cholesterol lowering, then there is no statistically convincing evidence of any increase in death from nonmedical causes (ie, suicide, violence, or accident). The recent meta-analysis that claimed such an effect<sup>1</sup>excluded 18 treated vs 23 control deaths from nonmedical causes in two of the trials and included four vs zero such deaths from outside the scheduled treatment period of another trial. Correction for both of these errors alters the total
Enhanced-potency polio vaccine nears licensing; policy to be studied
Authors: C. Marwick
Journal: JAMA (1987)

THE NEW ENHANCED-POTENCY inactivated polio vaccine (IPV) is nearing licensure by the Food and Drug Administration. Its advent brings a renewed interest in IPV use that is prompting the Institute of Medicine to do a review of polio vaccination policy in the United States. The last such review was in 1977. Studies by a number of investigators have shown that two doses of this inactivated enhanced-potency vaccine will induce virtually 100% seroconversion against all three types of poliovirus. This compares with currently available IPV, which requires four doses to provide full protection. Some data on serological responses to the new IPV were given at the 21st Immunization Conference in New Orleans by Roger H. Bernier, PhD, Centers for Disease Control (CDC), Atlanta. They came from a study done by A. Marshall McBean, MD, and his associates at Johns Hopkins University, Baltimore, in collaboration with the CDC. The study was recently
Hard people
Authors: F. Charatan
Journal: BMJ (2003)

<h3>Introduction/Background</h3> Indocyanine Green (ICG) is a fluorescent imaging agent which can be given intravenously or subcutaneously and detected using near-infrared light at laparoscopy. It can be injected para-cervically in order to identify pelvic sentinel nodes at laparoscopy. It can also be given intravenously in order to test tissue perfusion. <h3>Methodology</h3> In this study we have reviewed the use of this technology beyond pelvic sentinel nodes. We have identified four interesting cases for discussion. Case 1 - A total laparoscopic Hudson9s, pelvic and para-aortic node dissection, omentectomy with re-anastomosis and loop ileostomy was performed for endometrioid adenocarcinoma detected during prior excision of endometrioma. Following this procedure intravenous ICG was used to test perfusion at the bowel anastomosis. Case 2 - A total Laparoscopic hysterectomy was performed for Stage 1A endometrial cancer in a patient with a previous renal transplant. Following the procedure intravenous ICG was used to test perfusion to the transplanted kidney. Case 3 - A Laparoscopic trachelectomy and pelvic node dissection was performed for 1B cervical cancer with incomplete margins. Following this procedure intravenous ICG was used to test uterine perfusion. Case 4 - Open groin node dissection was performed on a patient with a squamous vulval cancer. Using the technology in the open setting, following subcutaneous injection of ICG around the tumor we were able to identify the sentinel groin node. <h3>Results</h3> We will show edited operative video of all cases mentioned above. <h3>Conclusion</h3> ICG technology has been shown to be a useful adjunct when performing sentinel node sampling. Through this presentation we have discussed a number of other interesting applications in the field of gynae-oncology. <h3>Disclosure</h3> Nothing to disclose.
Diabetic Neuropathies
Authors: Aaron I Vinik, Marie T Holland, Jean M Le Beau, Francis J Liuzzi, Kevin B Stansberry, Larry B Colen
Journal: Diabetes Care (1992)

Diabetic neuropathy is a common complication of diabetes that may be associated both with considerable morbidity (painful polyneuropathy, neuropathic ulceration) and mortality (autonomic neuropathy). The epidemiology and natural history of diabetic neuropathy is clouded with uncertainty, largely caused by confusion in the definition and measurement of this disorder. We have reviewed various clinical manifestations associated with somatic and autonomic neuropathy, and we herein discuss current views related to the management of the various abnormalities. Although unproven, the best evidence suggests that near-normal control of blood glucose in the early years after diabetes onset may help delay the development of clinically significant nerve impairment. Intensive therapy to achieve normalization of blood glucose also may lead to reversibility of early diabetic neuropathy, but again, this is unproven. Our ability to manage successfully the many different manifestations of diabetic neuropathy depends ultimately on our success in uncovering the pathogenic processes underlying this disorder. The recent resurgence of interest in the vascular hypothesis, for example, has opened up new avenues of investigation for therapeutic intervention. Paralleling our increased understanding of the pathogenesis of diabetic neuropathy, refinements must be made in our ability to measure quantitatively the different types of defects that occur in this disorder. These tests must be validated and standardized to allow comparability between studies and more meaningful interpretation of study results.
LOCAL ANESTHESIA
Authors: JAMES F. MITCHELL
Journal: JAMA (1913)

In 1907 at the meeting of the American Medical Association at Atlantic City, I presented a paper on local anesthesia and in the following year a report through the anesthesia commission on the extent to which it was used in this country. Since that time there have been important developments; the field has been broadened and the popularity of the method has increased both at home and abroad. It has seemed that a general review of this development might be of interest. Probably the one greatest factor has been the introduction of novocain as a substitute for cocain. First clinically tested by Heinrich Braun in 1905 and extolled by him in several papers,<sup>1</sup>it has been generally adopted and is now recognized as the best and safest substance for the production of local anesthesia. It has the great advantage of being about seven times less toxic than cocain, and
Industrial (Hospital) Therapy in a Veterans Administration Hospital (Chest Center)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment Outcome and Physician-Patient Communication in Primary Care Patients With Chronic, Recurrent Depression
Authors: T. L. Schwenk
Journal: American Journal of Psychiatry (2004)

OBJECTIVE: The authors' goal was to assess the adequacy of control, quality of life, and treatment experiences of patients with chronic, recurrent depression being treated by primary care physicians. METHOD: The sample comprised 1,001 patients 18 years old or older who had chronic, recurring depression and were currently being treated with a single antidepressant prescribed by a primary care physician. These patients had responded positively to questions regarding the presence of clinical depression and prescription of a single antidepressant by a primary care physician during a telephone survey conducted in two stages separated by 18 to 24 months. The 1,001 patients participated in a structured, 20-minute, anonymous interview conducted by trained personnel. RESULTS: Most patients had recurrent depression (median=5 episodes), and most had taken their current antidepressant for more than 1 year. The mean age at onset of depression was 33.8 years, and the mean age at time of diagnosis was 38.0 years, with treatment following a mean of 2 years later. Most patients were satisfied with the care they received from their primary care physician, but many also reported incomplete symptom resolution and substantial side effects from medications that were not discussed with or by their primary care physician. A majority of patients reported that treatment decisions were made in conjunction with their physician, a method that was preferred by three-quarters of the group. Although 752 patients reported that they had mild or moderate depression, 729 were satisfied with their life and 600 said they were in good or excellent health. CONCLUSIONS: Despite being mostly satisfied with the care received from their primary care physician, patients with chronic, recurring depression had substantial levels of continuing dysfunction, distress, unrelieved symptoms, and medication side effects, which suggests several possible physician-centered, patient-centered, or system-centered barriers to treatment to full function and wellness.
Foods for the Fat.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY: AN EFFECTIVE ASTHMA TREATMENT OPTION?" C. VOGELMEIER, A. D'URZO, R. PAUWELS, J.M. MERINO, M. JASPAL, S. BOUTET, I. NAYA AND D. PRICE. EUR RESPIR J 2005; 26: 819-828.
Journal: European Respiratory Journal (2005)
Sensitivity to fluorescent lighting.
Journal: BMJ (1969)

BJOURNA 185 lesions, which can be troublesome and very chronic,15 R. A.Cawson"' has recommended sucking pellets of betamethasone 17-valerate.Since many cases of both types of lichen planus are mild, corticosteroids should be reserved for patients suffer- ing appreciable symptoms that cannot be relieved by simple methods. Control of RabiesThe case of canine rabies reported in Britain last week must raise the question whether the quarantine imposed on imported dogs and cats is long enough.In fact the question might well be asked, Can any reasonable period of quarantine be certain to exclude rabies ?If it cannot, the import of animals capable of bringing the disease into the country should be altogether prohibited.This exceedingly dangerous disease is of virtually world- wide distribution.In recent years it has spread throughout the wild animals of Europe to a remarkable extent.Britain, like Australia, New Zealand, and some other islands, remains one
Woman's Auxiliary
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Urinary liver fatty-acid binding protein (UL-FABP) predicts acute-on-chronic liver failure (ACLF) and mortality in patients with decompensated cirrhosis
Authors: Adria Juanola, Isabel Graupera, Salvatore Piano, Chiara Elia, Cristina Solé, Octavi Bassegoda, Marta Carol, Núria Fabrellas, Marta Cervera, Martina Perez, Laura Napoleone, Elisa Pose, Ferran Torres, Elsa Solà, Pere Ginès
Journal: Journal of Hepatology (2020)
Medicine seeks to prevent more 'lost generations' of low-income children with avoidable problems
Authors: J. W. Zylke
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes
Authors: M Tapner
Journal: Hepatology (1996)

Administration of interferons of both the gamma and alfa/beta classes down-regulates hepatic cytochrome P450 (CYP) genes when administered to humans or rats. In male rats, interferons decrease expression of CYP3A2 at a pretranslational level, but because interferons also release other cytokines in vivo, it is unclear whether this is a direct effect on hepatocytes. We therefore examined the effects of rat recombinant interferon gamma (IFN-gamma) on CYP3A2, other 3A genes, and 2C11 in stable primary cultures of male rat hepatocytes. Hepatocytes were cultured on matrigel in Williams' E, and messenger RNAs (mRNAs) for 3A2, 3A1-like CYPs, and 2C11 mRNA were determined by RNase protection assays. CYP3A and 2C11 proteins were immunoquantified, and their catalytic activities were estimated by testosterone hydroxylation pathways. In control cells, 3A2 mRNA decreased initially but then recovered, and stable levels (15% of freshly isolated cells) were attained between days 3 and 7. Phenobarbital increased 3A2 mRNA to 60-120% values of freshly isolated cells, and mRNA for 3A1-like CYPs were increased 20-fold. In both control and phenobarbital-treated hepatocytes, rat recombinant IFN-gamma (33 U/mL) reduced mRNA for 3A2 and 3A1-like CYPs, as well as 3A protein and testosterone 6 beta-hydroxylase activity. Interferon had no effect on CYP2C11 at mRNA or protein levels in untreated cells, although a reduction in 2C11 protein was evident in phenobarbital-treated cultures. It is concluded that interferon directly alters expression of constitutive and inducible CYP3A genes in well-differentiated male rat hepatocytes in culture, but has no effect on constitutive expression of CYP2C11. (Hepatology 1996 Aug;24(2):367-73)
Address.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First-pass technique and diastolic phenomena.
Authors: R O Bonow, S L Bacharach, M V Green
Journal: Circulation (1982)

over distance significantly increased the correlation of SV 1 vs left ventricular (LV) mass (r = 0.60 to 0.71).This improvement is similar to our finding using the distance correction with the sum of SVI and RV5 or 6 vs LV mass (r = 0.68 to 0.84, p < 0.005) for a similar population.2However, we believe the formula used to derive this improvement is presented in error in their table 6.To correct for voltage attenuation over distance, the voltage should be multiplied, not divided, by the square of the left ventricle to recording electrode distance.We feel that their demonstration that echo is a better in- dicator of LV mass than ECG voltage (even with corrections for voltage attenuation over distance) is a most important observation.
SAT0053 Carotid Ultrasound is Useful for the Cardiovascular Risk Stratification of Patients with Rheumatoid Arthritis: Results of a Population-Based Study
Authors: A. Corrales, C. González-Juanatey, M. Peiró, R. Blanco, J. Llorca, V. Calvo-Río, J. Loricera, F. Ortiz-SanJuán, M. González-Gay
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Accelerated atherogenesis leading to increased incidence of cardiovascular (CV) mortality has been reported in patients with rheumatoid arthritis (RA). The search of tools that may identify high-risk RA patients who may benefit from active therapy to prevent CV events is of major importance. <h3>Objectives</h3> To determine if the use of carotid ultrasonography (US) may improve the stratification of CV risk of patients with RA. <h3>Methods</h3> A set of 370 consecutive patients without history of CV events was studied to assess carotid intima-media thickness (cIMT) and plaques. As previously proposed, CV risk was calculated according to the modified SCORE (mSCORE) for RA that was adapted by the application of a multiplier factor of 1.5 in those patients fulfilling ≥2 of 3 specific criteria. <h3>Results</h3> The mean disease duration was9.8years, 250 (68%) had rheumatoid factor/anti-CCP positivity and 61 (17%) extra-articular manifestations. Forty-three were excluded because they had type 2 diabetes mellitus or severe chronic kidney disease. CV risk was categorized in the remaining 327 RA patients according to mSCORE: mild (96 cases; 29.3%), moderate (201; 61.5%) and high/very high risk (30; 9.2%). Only 5 patients were reclassified as having high/very high CV risk when the mSCORE was applied. Severe carotid US abnormalities (cIMT &gt; 0.90 mm and/or plaques) were uncommon in patients with low mSCORE (13%). Nevertheless, in patients with moderate mSCORE severe carotid US abnormalities were observed in 63% of cases. Amodel that included a chart mSCORE risk ≥5% plus the presence of severe carotid US findings in patients with moderate mSCORE risk (≥1% and &lt;5%) yielded high sensitivity for high/very high CV risk (93 [95% CI: 88- 96]). <h3>Conclusions</h3> Carotid US assessment may be useful to establish the CV risk in RA, in particular in patients with moderate mSCORE. <h3>Acknowledgements</h3> This study was supported by grants from "Fondo de Investigaciones Sanitarias" PI06/0024, PS09/00748 and PI12/00060 (Spain). This work was also partially supported by RETICS Program, RD08/0075 (RIER) from "Instituto de Salud Carlos III" (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None Declared
Booknotes
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal